Search Results

By The ASCO Post Staff  / Thursday, March 7, 2013 2:45 PM

Focal Therapy Offers Middle Ground for Some Prostate Cancer Patients

Men with low-risk prostate cancer who previously had to choose between aggressive treatment, with the potential for significant side effects, and active surveillance, with the risk of disease progression, may have a new option. Focal laser ablation uses precisely targeted heat, delivered through a...

By The ASCO Post Staff  / Thursday, February 28, 2013 3:51 PM

Infusion of Stem Cells and Specially Generated T-cells from Same Donor Improves Leukemia Survival

In a significant advance for harnessing the immune system to treat leukemias, researchers at Fred Hutchinson Cancer Research Center have successfully infused large numbers of donor-derived T cells specific for a key antileukemic antigen in order to prolong survival in high-risk and relapsed...

By The ASCO Post Staff  / Tuesday, February 5, 2013 4:15 PM

High-dose Vorinostat Effective at Treating Relapsed Lymphomas, Study Finds

Reporting the results of a phase I clinical trial to test the effectiveness of a new class of drugs to augment standard chemotherapy, a team led by Fred Hutchinson Cancer Research Center scientists found that giving patients high doses of vorinostat (Zolinza) in combination with another round...

By The ASCO Post Staff  / Wednesday, January 23, 2013 1:43 PM

Nab-paclitaxel plus Gemcitabine Demonstrates Survival Advantage in Phase III Study of Patients with Advanced Pancreatic Cancer

Celgene International Sàrl announced on Tuesday that its phase III clinical trial of paclitaxel protein-bound particles for injectable suspension, albumin-bound (nab-paclitaxel, Abaraxane) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer...

Optimizing the Treatment of Acute Kidney Injury Caused by High-Dose Methotrexate: Integrating New Guidelines to Improve Patient Care

Patients receiving high-dose methotrexate (HDMTX) are at risk of developing acute kidney injury (AKI) due to delayed methotrexate clearance. New consensus guidelines aim to help the healthcare team optimize the treatment of AKI due to HDMTX and understand at which time points glucarpidase is most...